D. Gary Gilliland
- Hematology top 0.02%
- Acute Myeloid Leukemia Research 48
- Chronic Myeloid Leukemia Treatments 47
- Genetics top 0.05%
- Myeloproliferative Neoplasms: Diagnosis and Treatment 25
- Chronic Lymphocytic Leukemia Research 17
- Rheumatology top 0.2%
- Eosinophilic Disorders and Syndromes 20
- Molecular Biology top 0.5%
- Kruppel-like factors research 12
- Epigenetics and DNA Methylation 9
- Cancer Research top 1%
-
- Acute Lymphoblastic Leukemia research 19
- Co-authors
- Todd R. GolubBrian J.P. HuntlyGeorge F. BarkerMichael LovettLouise KellyNancy A. SpeckZuzana TóthováAyalew Tefferi
- Cited by
- HematologyGeneticsRheumatology
- Partner nations
- United StatesGermanyFrance
In The Last Decade
D. Gary Gilliland
126 papers receiving 15.8k citations
Hit Papers
Peers
Comparison fields: 5 of 138
- Hematology 8.1k
- Genetics 4.2k
- Rheumatology 2.0k
- Molecular Biology 8.4k
- Cancer Research 1.7k
Countries citing papers authored by D. Gary Gilliland
This map shows the geographic impact of D. Gary Gilliland's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by D. Gary Gilliland with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites D. Gary Gilliland more than expected).
Fields of papers citing papers by D. Gary Gilliland
This network shows the impact of papers produced by D. Gary Gilliland. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by D. Gary Gilliland. The network helps show where D. Gary Gilliland may publish in the future.
Co-authorship network
The 25 scholars most cited alongside D. Gary Gilliland, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2024 | 10 | |
| 2 | 2017 | 145 | |
| 3 | 2012 | 151 | |
| 4 | 2011 | 37 | |
| 5 | Akt/foxo signaling pathway enforces the differentiation blockade in myeloid leukemias | 2011 | 1 |
| 6 | 2011 | 217 | |
| 7 | 2010 | 30 | |
| 8 | Musashi-2 regulates normal hematopoiesis and promotes aggressive myeloid leukemia | 2010 | 2 |
| 9 | 2010 | 13 | |
| 10 | 2008 | 66 | |
| 11 | The Retinoblastoma Binding Protein RBP2 Is an H3K4 Demethylasebreakdown → | 2007 | 336 |
| 12 | 2006 | 52 | |
| 13 | 2006 | 161 | |
| 14 | 2006 | 11 | |
| 15 | 2004 | 52 | |
| 16 | Identification and characterization of a novel activating mutation of the FLT3 tyrosine kinase in AML | 2004 | 3 |
| 17 | 2004 | 46 | |
| 18 | Differentiation block in FLT3 mutant AML by inactivation of C/EBPalpha function by phosphorylation | 2003 | 1 |
| 19 | Intensified therapy for infants with acute lymphoblastic leukemia: results from the Dana-Farber Cancer Institute Consortium. | 1997 | 81 |
| 20 | 1994 | 60 |
About D. Gary Gilliland
D. Gary Gilliland is a scholar working on Hematology, Genetics and Rheumatology, having authored 126 papers that have together received 16.2k indexed citations. Recurring topics across this work include Acute Myeloid Leukemia Research (48 papers), Chronic Myeloid Leukemia Treatments (47 papers), Myeloproliferative Neoplasms: Diagnosis and Treatment (25 papers), Eosinophilic Disorders and Syndromes (20 papers), Acute Lymphoblastic Leukemia research (19 papers), Chronic Lymphocytic Leukemia Research (17 papers), Kruppel-like factors research (12 papers) and Epigenetics and DNA Methylation (9 papers). The work is most often cited by research in Hematology (8.1k citations), Genetics (4.2k citations) and Rheumatology (2.0k citations). D. Gary Gilliland has collaborated with scholars based in United States, Germany and France. Frequent co-authors include Todd R. Golub, Brian J.P. Huntly, George F. Barker, Michael Lovett, Louise Kelly, Nancy A. Speck, Zuzana Tóthová, Ayalew Tefferi, Jacob M. Rowe and Martin S. Tallman. Their work appears in journals such as Nature, New England Journal of Medicine and Cell.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.